Lung Cancer Mutation Consortium Protocol
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Stage IIIB/IV Adenocarcinoma
Both
Stage IIIB/IV Adenocarcinoma
Trial Information
Lung Cancer Mutation Consortium Protocol
Inclusion Criteria:
1. Subjects (=> 18 years of age) who are undergoing further evaluation for the diagnosis
or treatment of advanced adenocarcinoma of the lung.
2. Oral and written informed consent.
Exclusion Criteria:
1. Any individual who does not give oral and written consent for participation.
2. Lung cancer histologies other than adenocarcinoma
3. Lack of adequate tissue.
Type of Study:
Observational
Study Design:
Time Perspective: Retrospective
Outcome Measure:
The primary objective of this protocol is to determine the frequency of oncogenic mutations in patients with advanced adenocarcinoma of the lung. The primary endpoint of this protocol is the mutation rate.
Outcome Time Frame:
Five years
Safety Issue:
No
Principal Investigator
Paul Bunn, M.D.
Investigator Role:
Study Director
Investigator Affiliation:
University of Colorado, Denver
Authority:
United States: Institutional Review Board
Study ID:
09-0756
NCT ID:
NCT01014286
Start Date:
September 2009
Completion Date:
June 2014
Related Keywords:
- Stage IIIB/IV Adenocarcinoma
- Adenocarcinoma
- Adenocarcinoma, Mucinous
- Lung Neoplasms
Name | Location |
|---|---|
| University of Colorado Denver Cancer Center | Aurora, Colorado 80045 |
